A detailed history of Blair William & CO transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Blair William & CO holds 59,902 shares of SGMO stock, worth $122,200. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,902
Previous 124,902 52.04%
Holding current value
$122,200
Previous $83,000 74.7%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$0.36 - $0.65 $23,400 - $42,250
-65,000 Reduced 52.04%
59,902 $21,000
Q4 2023

Feb 12, 2024

SELL
$0.3 - $0.63 $45,000 - $94,500
-150,000 Reduced 54.56%
124,902 $67,000
Q3 2023

Nov 09, 2023

SELL
$0.58 - $1.47 $11,600 - $29,400
-20,000 Reduced 6.78%
274,902 $164,000
Q4 2022

Feb 10, 2023

SELL
$2.77 - $5.07 $138,500 - $253,500
-50,000 Reduced 14.5%
294,902 $925,000
Q4 2021

Feb 14, 2022

BUY
$7.29 - $10.97 $2.51 Million - $3.78 Million
344,902 New
344,902 $2.59 Million

Others Institutions Holding SGMO

About SANGAMO THERAPEUTICS, INC


  • Ticker SGMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 156,552,992
  • Market Cap $319M
  • Description
  • Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...
More about SGMO
Track This Portfolio

Track Blair William & CO Portfolio

Follow Blair William & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.